J.P.H. van Wijk
Utrecht University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J.P.H. van Wijk.
Journal of Internal Medicine | 2004
C.J.M. Halkes; J.P.H. van Wijk; J. Ribalta; L. Masana; M. Castro Cabezas
Objective. A novel method has been developed to study diurnal triglyceride (TG) profiles using repeated capillary self‐measurements in an ‘out‐of‐hospital’ situation. We assessed the diurnal capillary TG (TGc) profile in males with mild obesity and evaluated the use of plasma and capillary TG as markers of insulin resistance.
Atherosclerosis | 2009
A. Alipour; A.J.H.H.M. van Oostrom; J.P.H. van Wijk; C. Verseyden; H.W.M. Plokker; J.W. Jukema; A.J. Rabelink; M. Castro Cabezas
Mannose binding lectin (MBL) is one of the three initiators of complement activation and is therefore closely linked to inflammation. MBL deficiency has been associated with the generation of atherosclerosis. Since atherosclerosis, the complement system and postprandial lipemia are linked to inflammation, we studied postprandial lipoprotein metabolism in MBL deficiency. An observational study was carried out in 107 volunteers (21% MBL deficient). Classical cardiovascular risk factors were not different between subjects with and without MBL deficiency. Oral fat loading tests in 8 MBL deficient and 14 MBL sufficient subjects showed similar postprandial triglyceride, free fatty acid, hydroxybutyric acid and complement component 3 concentrations. MBL deficient subjects had 2.4 times lower postprandial Sf>400 (chylomicron)-apoB48 concentrations, but in contrast a 2-3.5 times increased Sf 60-400 (VLDL1-TG) and Sf 60-400-apoB100 response. MBL activity was inversely related to the postprandial Sf 60-400-TG increase. Despite lower postprandial Sf>400-apoB48 concentrations, MBL deficient subjects show an accumulation of Sf 60-400 lipoproteins.
Metabolism-clinical and Experimental | 2003
J.P.H. van Wijk; C.J.M. Halkes; D.W. Erkelens; M. Castro Cabezas
Atherosclerosis | 2006
J.P.H. van Wijk; M. Castro Cabezas; Blai Coll; Jorge Joven; Ton J. Rabelink; E. J. P. de Koning
Atherosclerosis | 2005
J.P.H. van Wijk; Rudolf J.A Buirma; A. van Tol; C.J.M. Halkes; P.P.Th. de Jaegere; H.W.M. Plokker; Y.J.M. van der Helm; M. Castro Cabezas
The Journal of Clinical Endocrinology and Metabolism | 2005
J.P.H. van Wijk; M. Castro Cabezas; E. J. P. de Koning; T.J. Rabelink; R.J. van der Geest; I.M. Hoepelman
Atherosclerosis | 2003
J.P.H. van Wijk; C.J.M. Halkes; P.P.Th. de Jaegere; H.W.M. Plokker; D.W. Erkelens; M. Castro Cabezas
The Journal of Clinical Endocrinology and Metabolism | 2012
J.P.H. van Wijk; H. S. Broekhuizen-de Gast; A. J. J. Smits; M. E. I. Schipper; Pierre Zelissen
Atherosclerosis Supplements | 2004
J.P.H. van Wijk; C.J.M. Halkes; P. De Jaegere; H.W.M. Plokker; M. Castro Cabezas
Atherosclerosis Supplements | 2011
B. Klop; A.J.H.H.M. van Oostrom; J.P.H. van Wijk; Arash Alipour; Erwin Birnie; J.W.F. Elte; Jeffrey S. Cohn; M. Castro Cabezas